Testing effectiveness (Phase 2)Study completedNCT05061017
What this trial is testing
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
Who this might be right for
NSCLCMetastatic Colorectal CarcinomaRefractory Melanoma
Diwakar Davar 13